



SCOPE FLUIDICS

EDOCERA & HYBOLIC

28 October 2026

DISCLAIMERS



This presentation (“Presentation”) contains basic information about Scope Fluidics S.A. (“the Company”) and the Scope Fluidics S.A. Group (“the Group”).

This presentation has been prepared solely for the purpose of providing basic information about the Group and its operations. It does not present complete data regarding the Group’s operations, financial condition, assets, or legal status, which may be required to make an investment decision regarding the Group or the financial instruments of its subsidiaries. The Company has taken measures to ensure that the data presented is fully reliable; however, it cannot and should not be treated as such. All forecasts, opinions, and projections contained in the Presentation, including the Company’s projections, opinions, and forecasts, were prepared as part of routine analytical activities and should not be treated as information approved by any third party. Although measures have been taken to ensure that the facts stated in the Presentation are accurate and that the forecasts, opinions, and projections are reliable and reasonable, the Company has not verified their completeness or accuracy.

Consequently, neither the Company nor any of its shareholders or advisors, their affiliates, members of governing bodies, or employees shall be liable, on any basis whatsoever, for the content of the Presentation.

When making investment decisions or acting for any other purpose, one should not rely on the information contained in the Presentation, including with respect to its accuracy, reliability, and completeness. None of the entities listed above accepts any liability, on any basis, for any damages arising from the use of this document and the information contained therein.

The statements contained in the Presentation should not be treated as assurances or guarantees by the Company or as commitments or promises regarding the Group’s future financial or operating results. The content of the Presentation does not constitute, nor should it be treated as, investment, legal, or tax advice. Recipients of the Presentation should independently seek appropriate investment, legal, or tax advice.

This presentation does not constitute an offer, in particular within the meaning of the Act of July 29, 2005, on Public Offerings and the Conditions for Introducing Financial Instruments to an Organized Trading System, and on Public Companies (Journal of Laws, consolidated text 2013.1382 as amended) or the Act of April 23, 1964—Civil Code (Journal of Laws, consolidated text 2014.121, as amended), a recommendation, or an invitation to subscribe for or purchase bonds.

Neither the Presentation nor any part thereof constitutes any contract or any obligation regarding the performance of such a contract. The Company reserves the right to amend or supplement the Presentation at any time, although it is under no obligation to do so, nor is it obligated to make any updates or corrections to the content of the Presentation, or to provide additional information about the Company or the Group.

Presenters



MARCIN IZYDORZAK

SCOPE FLUIDICS

VICE PRESIDENT



MACIEJ LIRSKI

HEAD OF HYBOLIC

- **Ph.D. scientist with 12+ years in biotechnology, including 6+ years leading multidisciplinary MedTech R&D.**
- **Product development from concept through prototyping, industrialization and CE-IVD registration under ISO 13485.**
- **Experience in IP development, patenting, and a key role in technical due diligence for the \$130M acquisition by Bio-Rad**




MATEUSZ BEDNARSKI

HEAD OF EDOCERA

- **14 years in new product development, including MedTech — design to registration under MDD/MDR (EU) and FDA (US).**
- **Commercial and operational reach across 15+ countries on 3 continents: EU/US sourcing, supplier onboarding, 10+ audits in China and India, plus EU grant funding secured.**


VENTURE STUDIO - OUR VALUES AND VISION FOR SUCCESS

- We address **global challenges in healthcare** and develop technologies with real, global impact
- We aim at **+USD 10⁹ markets and develop technologies that can readily be leveraged by large, multinational and global med-tech operators**
- We develop companies as attractive acquisition targets for global strategic investors with valuations in multiples of USD 100 mln



How we operate at Scope Discovery

Systemic selection and development of new projects



Corporate structure supports execution of M&A transactions



Each project in Scope Fluidics' Group is **developed in a separate, legal entity (SPV)**



Each subsidiary is focused on the R&D activities and has the full ownership of all the IP relevant to its project, employment, commercial contracts, and all relevant certifications



Scope Fluidics provides SPVs with back-office functions, such as HR, finance, reporting, legal, regulatory, etc.



Sold to Bio-Rad Laboratories
August 2022

SUBSIDIARY #1



Started in 2012



100% ownership of the SPVs

SUBSIDIARY #2



Started in 2017



SUBSIDIARY #3

EDOCERA
Prevention and ongoing diagnostics for patients at risk of stroke

Started in 2024



SUBSIDIARY #4

HYBOLIC
Comprehensive solution for patients with metabolic syndrome

Started in 2025





Early metabolic diagnosis


Insulin and glucose, measured together



Three booms are already happening


Glucose sensors (CGM)

Dexcom revenue, USD bn (almost all CGM)




GLP-1 drugs

Novo Nordisk + Eli Lilly GLP-1 sales, USD bn



Personal health

Function Health members




Sources: Dexcom annual results 2014–2025 · Novo Nordisk (DKK at Novo's average USD rates) and Eli Lilly annual results 2017–2025 · Fast Company 2024, Athletech News 2026



THE MARKET

Metabolic brands are valued at USD 2.5–11 bn



Consumer metabolic brands raised money at these valuations in 2025 and 2026.

Dexcom's over-the-counter glucose sensor passed 500,000 users in under two years on the market.


Sources: Oura and WHOOP releases (Business Wire, Oct 2025 and Mar 2026) · Fierce Healthcare, Nov 2025 · Dexcom investor presentation, Apr 2026



THE MARKET

People already pay to measure themselves

Members and users of consumer metabolic products



Home use


for both Hybolic products

The PoC test and continuous monitoring are intended, in the long run, for private use at home.



THE NEED

Insulin moves a decade before glucose



26.5%

of adults are insulin resistant
≈ 1.4 bn people worldwide

589 M

adults live with diabetes
nearly one in nine

635 M

have impaired glucose tolerance
the step before diabetes

We have to start measuring insulin.

Schematic, not to scale, after Tabák et al., Lancet 2009 (Whitehall II) and Warram et al., Ann Intern Med 1990 · Ballena-Caicedo et al., Front Endocrinol 2025 · IDF Diabetes Atlas 2025



THE CONCLUSION

Glucose alone built a USD 14 bn market. Insulin is the other half, and nobody measures it outside the lab.

Whoever brings insulin to the doctor's office and into daily life will own the next layer of metabolic health.



HYBOLIC

Two large markets, and we can win them

≥ USD 3 bn

a year: PoC test

insulin testing in PCOS, prediabetes, obesity and GLP-1 care, fatty liver and pregnancy

≈ USD 18 bn

a year: wearable

insulin for every glucose-sensor user, plus short monitoring episodes

Ceilings from our market model: the whole world, revenue to Hybolic, a mature market.

We have what it takes to get there

The idea

The people

The backing

Company estimate, Hybolic market model (Oct 2026), from CGM filings, CMS and French insurance test volumes and IDF data · PoC test scaled from US, EU-5 and Poland by WHO health-spending shares



Where we stand: from validation to proof of concept

Progress to date

- ✓ A dedicated company, with an in-house R&D team and laboratory
- ✓ Sensing methods confirmed in lab settings; key parameters and failure modes established
- Currently: confirming repeatability, on the way to proof of concept

EU grant

PLN 14.4 M

Agreement with PARP signed, towards PLN 24.1 M of project costs, for a system that measures insulin and glucose together.

Backing A Scope Fluidics company; external equity can join directly at the Hybolic level.




POC TEST

One visit instead of two


Today

lab path



PoC test

Hybolic target



Poland example; lab protocol from ALAB product page · PoC test = design targets

2 → 1

visits to a decision

same visit

instead of the next working day

in the office


no transport, no second appointment



POC TEST

Doctors want it, offices are ready, buyers are active

82% of 79 physicians would fit a short insulin test into their own visit



114k

US physician-office labs

74% run only simple waived tests, like the HbA1c analysers Abbott Afinion and Siemens DCA Vantage

6

repeat buyers


Danaher, Roche, bioMérieux, Abbott, QuidelOrtho and Meridian keep buying point-of-care makers



WEARABLE

Insulin turns a diabetes tool into a mass market

Who it can serve



SIGNAL WITHOUT DIABETES

CGM: glucose in the normal range 96% of the time

Insulin + glucose: insulin moves years earlier

FEEDBACK FOR ACTION

CGM: same meal, a different curve each time

Insulin + glucose: responds to meals, training and drugs

MARKET


CGM: USD 14 bn, over-the-counter only ~1%

Insulin + glucose: a new market beyond diabetes



WEARABLE

A USD 14 bn glucose-sensor market today



~12 M

people on a glucose sensor today

of the 70–80 M who should be, according to Abbott's CEO

6


repeat buyers

Medtronic, Roche, Dexcom, Tandem, Oura and Philips keep buying wearable makers

CGM sales 2025: Abbott 10-K, Dexcom FY2025 release, Medtronic MiniMed, Senseonics, MicroTech and i-SENS filings; others = Hybolic assumption · Abbott CEO via Drug Delivery Business, Apr 2026 · deal announcements 2001–2026



Nobody measures insulin for everyday decisions



THE PRIZE

The prize: from a USD 130 M exit to a USD 10 bn platform

Pre-revenue point-of-care deal

median of 5 deals, headline values

USD 142 M

Curiosity → Bio-Rad

Scope Fluidics, 2022, paid in total

USD 130 M

Point-of-care company with revenue

median of 13 deals

USD 450 M

Wearable medical monitoring with revenue

median of 9 deals

USD 538 M

Function Health

valuation, Nov 2025

USD 2.5 bn

WHOOP

valuation, Mar 2026

USD 10.1 bn

Oura

valuation, Oct 2025

USD 11 bn

100 M

1 bn

10 bn

log scale · deal medians: headline values · valuations: private funding rounds

Sources: Hybolic analysis of announced point-of-care and wearable medical deals, 2001–2026, headline values (medians: 5, 13 and 9 deals) · valuation announcements 2025–2026





Stroke Risk Monitoring System

Our vision is to detect stroke
before visible symptoms appear

PROBLEM

Stroke onset often goes unobserved

1 in 5 people

will have an ischemic stroke in their lifetime

~8 million

acute ischemic strokes occur every year globally

1 in 3 strokes


have an unknown onset, including strokes during sleep

No existing system was built for stroke monitoring

The monitoring gap creates the Edocera opportunity

SOLUTION

Edocera gets patients inside the treatment window



PRODUCT

We build a three-layer system for early stroke detection

WEARABLE DEVICE

Recording of raw multimodal physiological signals from the patient's body



AI ENGINE AND CLOUD

AI-supported signal analysis, secure data storage and clinician access




INTEGRATED APP

Stroke-risk alert system for patients, caregivers and emergency contacts



PATHWAY

Our product will connect the patient to stroke care faster



Today:

Symptoms unwitnessed
or noticed late



Hospital

With Edocera:

Alert at first signs



Hospital

OUR APPROACH

We listen to patients, doctors and science

EARLY SCIENTIFIC VALIDATION

380+

scientific articles
analyzed



VALIDATED CLINICAL DEMAND

1,000+

interviews and
opinions collected



GROWING CLINICAL NETWORK

10+

key opinion leaders
engaged



Our work is gaining recognition in Poland and abroad

2025

MedX@Düsseldorf Winner

Won a direct invitation to MEDICA 2025, the world's leading medical trade fair.

Start-ups Are Us Winner

Chosen as one of 16 start-ups by PARP for missions to the UAE, Germany and Singapore.

Deep Tech CEE Challenge Top 75

Ranked among the leading deep-tech ventures in Central & Eastern Europe.

2026

Seal of Excellence Awarded

Granted by the European Commission to projects passing all EU funding thresholds.

PARP Grant Recipient, PLN 12.2M

Conditionally awarded by PARP for a medical device supporting stroke prevention and diagnostics.

Digital Health Pitch Day Finalist

Selected from 100+ applicants to pitch on stage in Munich in November.

MARKET OPPORTUNITY

We are addressing a large, high-growth market

TAM

\$9.60B

Globally addressable

Acquisitions in this space

Boston Scientific acquired
Silk Road Medical

Stroke-prevention
vascular device

\$1.18B

Boston Scientific acquired
Preventice

Wearable heart
monitor

\$925M

Medtronic acquired
Scientia Vascular

Stroke-related
cerebrovascular device

\$550M


Johnson&Johnson acquired
Laminar

Left atrial appendage
elimination device

\$400M

KEY MILESTONES

We deliver on time and under budget, reducing risk step by step



Q&A session





THANK YOU

INVESTOR RELATIONS

relacjeinwestorskie@scopefluidics.com